Search clinical trials for: ZD6474 (vandetanib) 100mg

Total 2507 results

Genzyme, a Sanofi Company

Completed

ZD6474 Phase IIa Dose Finding Multicentre Study

Non Small Cell Lung Carcinoma

Japan
Genzyme, a Sanofi Company

Completed

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma

Japan
Phloronol Inc.
Worldwide Clinical Trials

Completed

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

Safety Issues

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Xuanwu Hospital, Beijing

Completed

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

Parkinson Disease

China
Inmagene LLC

Recruiting

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
Genzyme, a Sanofi Company

Completed

ZD6474(Vandetanib) + Alimta Combo Study

Carcinoma | Lung Cancer | Non-Small Cell Lung
National Cancer Institute (NCI)

Completed

Phase II Study of Vandetanib in Individuals With Kidney Cancer

Renal Cancer | Von Hippel Lindau

United States
M.D. Anderson Cancer Center
United States Department of Defense; AstraZeneca

Completed

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

Lung Cancer

United States
St. Jude Children's Research Hospital

Completed

Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma

Brain and Central Nervous System Tumors

United States
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Genzyme, a Sanofi Company

Completed

Phase I Chinese PK

Advanced Solid, Malignant Tumors

China
Genzyme, a Sanofi Company

Active, not recruiting

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Thyroid Cancer

United States, Italy, Poland, Russian Federation, United Kingdom, Netherlands, Israel, Czechia, India
Genzyme, a Sanofi Company

Completed

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

Thyroid Cancer

United States, France
Ensol Bioscience

Completed

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

Healthy

Korea, Republic of
Genzyme, a Sanofi Company

Completed

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Thyroid Cancer

Italy, Spain, Romania, Netherlands, Canada, United States, Switzerland, Australia
Genzyme, a Sanofi Company
Worldwide Clinical Trials

Completed

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (Caprelsa104)

Symptomatic, Aggressive, Sporadic, Unresectable, Locally | Advanced/Metastatic Medullary Thyroid Cancer (MTC)

Belgium, Italy, Netherlands, Spain, France, Germany, United Kingdom, Luxembourg
University of Chicago
National Cancer Institute (NCI)

Completed

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Precancerous Condition | Lip and Oral Cavity Squamous Cell Carcinoma | Oral Cavity Verrucous Carcinoma

United States
Genzyme, a Sanofi Company

Active, not recruiting

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Thyroid Cancer

United States, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Sweden, Switz...
Dong Wha Pharmaceutical Co. Ltd.

Completed

To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Korea, Republic of
Sanofi

Terminated

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

Non-small Cell Lung Cancer (NSCLC)

Netherlands
Medicines for Malaria Venture

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

Healthy Volunteers | Malaria Falciparum | Malaria Vivax

United States
Genzyme, a Sanofi Company

Completed

Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Taiwan
National Cancer Institute (NCI)

Terminated

Vandetanib to Treat Advanced Kidney Cancer

Advanced Clear Cell Renal Carcinoma

United States
Genzyme, a Sanofi Company

Completed

Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer

Colorectal Cancer

Germany
MyMD Pharmaceuticals, Inc.

Completed

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

Frailty | Sarcopenia | Aging

United States
University of Colorado, Denver
AstraZeneca

Completed

Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas (IRUSZACT0073)

Malignant Gliomas

United States
Vigonvita Life Sciences

Completed

Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers

Healthy Subjects

China
M.D. Anderson Cancer Center
AstraZeneca

Terminated

Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
National Cancer Institute (NCI)

Terminated

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Ronald Weigel
AstraZeneca

Terminated

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

Invasive Breast Cancer

United States
National Cancer Institute (NCI)

Completed

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

Glioblastoma Multiforme | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Anaplastic Mixed Oligoastrocytoma

United States
Shanghai Jiatan Pharmatech Co., Ltd

Completed

Sudapyridine (WX-081) in Healthy Volunteers

Healthy

China
Genzyme, a Sanofi Company

Completed

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Adenocarcinoma | Metastatic | Colorectal

United Kingdom, Belgium
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
Bio-Thera Solutions

Completed

A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients

Non-Hodgkin's Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

Acute Myeloid Leukemia

China
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Terminated

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Relapsed Lymphoid Malignancies | Refractory Lymphoid Malignancies

Australia
NeuroBo Pharmaceuticals Inc.
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathy

Diabetic Neuropathy

United States
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathic Pain

Diabetic Neuropathies

Korea, Republic of
Genzyme, a Sanofi Company

Terminated

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial (ZACFAST)

Breast Cancer

Italy
OSE Immunotherapeutics

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Advanced Tumor

France, Belgium
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
Genzyme, a Sanofi Company

Completed

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Non-Small-Cell Lung Carcinoma

United States, France, Italy, Korea, Republic of, Peru, Spain, United Kingdom, Philippines, China, Germany, Hong Kong, Argentina, Austria, Canada, Israel, Taiwan, Mexico, Thailand, Belgium, Australia, Singapore, Netherlands
Sanofi

Completed

Open Label, Phase I ZD6474 Head and Neck Cancer Study

Head and Neck Cancer

United States
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Netherlands
Genzyme, a Sanofi Company

Completed

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Colorectal Cancer

United States, Korea, Republic of, Spain, United Kingdom, Norway, Argentina

Search clinical trials for: ZD6474 (vandetanib) 100mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations